Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR-TKI vs EGFR-TKI + WBRT in EGFR-Mutant NSCLC with Brain Metastasis
NCT02714010Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2015
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of gefitinib, erlotinib, icotinib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02714010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02714010.